

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Meloxicam Nanocrystal Injection (the “**Product**”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Company, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

Meloxicam is a selective nonsteroidal anti-inflammatory drug mainly used to treat chronic pain in osteoarthritis and rheumatoid arthritis. It is available in the dosage form of oral preparation and intramuscular injection in China. The Product is being developed through novel nanocrystal technology, with the reduction of drug particle size to nanometer range, it could achieve high dose, rapid intravenous administration as well as rapid, powerful and long-lasting analgesic effects.

Opioids are most commonly used for the treatment of moderate-to-severe pain. However, they can lead to serious adverse reactions such as respiratory depression, excessive nausea and vomiting as well as addiction. The Product, as a non-opioid medication, only requires 1 dose per day, which may provide a better alternative in the management of moderate-to-severe pain for adults.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 5 January 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

** For identification purposes only*